Radiation therapy for kidney cancer that has spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing whether high-dose radiation therapy can safely treat kidney cancer that has spread to a few spots in the body, either when it is first found or when it grows during standard drug treatment. The goal is to see if this approach is effective and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your kidney cancer must have spread to other parts of the body (or progressed during systemic therapy).
- You must be able to tolerate high-dose radiation to all metastatic sites, as decided by a radiation oncology doctor.
- You must be able to receive standard systemic therapy (like targeted therapy or immunotherapy).
- You must not have had radiation to the same site before, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.